HHS' Azar Defends Value Of "Me Too" Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Government market controls stifle innovation and patient access to care, HHS deputy secretary says.
You may also be interested in...
HHS’ Azar Departing To Explore Private Sector Opportunities
Deputy Sectary to leave after five and a half years with department; no successor announced.
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: